Owens&Minor Mergers and Acquisitions Presentation Deck

■ Adding approximately $1.2 billion of annual net revenue ▪ Adds in excess of $230 million in incremental adjusted EBITDA, implying ~20% margin ▪ Annual capex requirements of ~$100 million ▪ FCF generation > $80 million Leverage Ratio to increase to just under 4x TTM adjusted EBITDA Expect to return to targeted leverage range of 2-3x within 24 months No changes to capital allocation priorities Deleverage the balance sheet Re-invest organically in broader business to drive top-line growth / bottom-line efficiencies Expect to change segment reporting structure beginning with 1Q22 filings Patient Direct = Byram + Apria Products & Healthcare Services = Global Products + Medical Distribution and Services Reiterating 2022 guidance for existing business EXCLUDING APRIA - Adjusted EPS of $3.00 - $3.50 Adjust EBITDA of $400 - $450 million Transaction will be accretive to EPS in 2022 assuming 1H22 close I ● ● ● ● Annualized Financial Impact (pre-synergies) 6 - - Confidential & Proprietary to Owens & Minor, Inc. - Pro-Forma Net Revenue (~$10.5B) Patient Direct ~20% Products & Healthcare Services ~80% Pro-Forma Adjusted EBITDA (~$650M) Products & Healthcare Services ~51% Patient Direct ~49% Owens M&Minor

View entire presentation